Results 221 to 230 of about 250,617 (262)
Some of the next articles are maybe not open access.
Innovations & Thérapeutiques en Oncologie, 2015
Les cellules CAR-T se presentent comme une revolution en matiere d’immunotherapie grâce aux progres de l’ingenierie cellulaire qui contournent les mecanismes d’echappement tumoraux. Les progres recents pour ameliorer leur specificite et securite en font une nouvelle arme contre le cancer.
Edouard Forcade, Pierre-Yves Dumas
openaire +1 more source
Les cellules CAR-T se presentent comme une revolution en matiere d’immunotherapie grâce aux progres de l’ingenierie cellulaire qui contournent les mecanismes d’echappement tumoraux. Les progres recents pour ameliorer leur specificite et securite en font une nouvelle arme contre le cancer.
Edouard Forcade, Pierre-Yves Dumas
openaire +1 more source
C&EN Global Enterprise, 2018
Last August, in a milestone decades in the making, Kymriah became the first cell therapy to be approved by the U.S. Food & Drug Administration. Marketed by the Swiss giant Novartis, Kymriah is made by genetically engineering an individual’s own immune cells to attack a form of leukemia.
openaire +1 more source
Last August, in a milestone decades in the making, Kymriah became the first cell therapy to be approved by the U.S. Food & Drug Administration. Marketed by the Swiss giant Novartis, Kymriah is made by genetically engineering an individual’s own immune cells to attack a form of leukemia.
openaire +1 more source
Blood
Abstract Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed and refractory B-cell malignancies. There is limited understanding of how Canada's large geographic area impacts CAR-T delivery and treatment response.
Bradley Rutherford +7 more
openaire +1 more source
Abstract Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed and refractory B-cell malignancies. There is limited understanding of how Canada's large geographic area impacts CAR-T delivery and treatment response.
Bradley Rutherford +7 more
openaire +1 more source
MedScien
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors.
openaire +1 more source
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors.
openaire +1 more source
Tracing the Path of CAR T Cells
Cancer Discovery, 2017Abstract Adding a radioactive tag to CAR T cells has allowed these engineered cells to be monitored as they home in on brain tumors in patients. The technique could help promote a deeper understanding of why this immunotherapy isn't more broadly effective, and why resistance sometimes develops.
openaire +2 more sources
The cellular orchestra of CAR T success
Cancer CellIn this issue of Cancer Cell, Rade et al. report a longitudinal single-cell atlas of multiple myeloma patients receiving BCMA-directed chimeric antigen receptor (CAR) T cell therapy (ide-cel or cilta-cel) and identifiy features linked to long-term responses, including CD4+ T cell-driven cytotoxicity, memory-biased T cell states, reduced exhaustion, and
Mehmet Kemal, Samur, Nikhil C, Munshi
openaire +2 more sources
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly